Back to top

Syndax sees Revuforj U.S. peak net revenue in excess of $2B as Q4 axatilimab readouts approach

Syndax sees Revuforj U.S. peak net revenue in excess of $2B as Q4 axatilimab readouts approach

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Syndax Pharmaceuticals, Inc. (SNDX)